Replies to post #398519 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Thanks, Lykiri. May be I will attend in person. We will see.

[jesster64]

Thank You Lykiri.
This part stands out to me at first glance
"• Exploring immune therapy resistance in glioblastoma."
I would think they would support this with data from trials. JMO

[CaptainObvious]

Lol, first reference to a next year event, methinks

[HappyLibrarian]

This could provide more insight assuming it’s not another ‘placeholder’ appearance that gets cancelled but nothing in the description would require Dr. Bosch to have TLD in hand since it is a general talk about the field.

[ATLnsider]

Thank you Lykiri

[ATLnsider]

I like this talk on Day 1 at 3:00 PM. This will be important for future inoperable GBM solid tumor cancer indication ndGBM and rGBM approvals for DCVax Direct:

[sentiment_stocks]

Excellent discovery, as usual.

His title seems like a relatively safe one, IMO, that can move forward to cover trial data (fingers crossed), or stay general if it must.

[flipper44]

“Optimizing” goes straight to the very recently allowed Direct patent, imo. I could try my best to tie this all together tonight, but I’ll opt for a relaxing weekend.

I do hope there comes a day when these folks could stop with the cryptic conference titles. Anyway,I think this is good news and will address a post TLD world that will have started to unfold this year.

[pgsd]

I find it interesting that it was initially scheduled for December with LL speaking on the 6th and 7th December, details of which have now been taken down.


https://glioblastoma-drugdevelopment.com/speaker/josh-allen/

[eagle8]

Great detective work Lykiri. As always.

Thank you for sharing.


GLTU

[anders2211]

thank you Lykiri,

at least we know for sure that in January 2022 NWBO will be out of its never deep winter sleep.

[anders2211]

Marnix Bosch
Chief Technology Officer
NorthWest Biotherapeutics
11.40 am Immunotherapy of Brain Cancer: Past, Present and Future.

• Challenges of designing & evaluating clinical trials for
immunotherapies in the GBM field.
• Strategies to sensitize glioblastoma to immune therapies.
• Exploring immune therapy resistance in glioblastoma

why would Dr Bosch want to talk about the evaluating of clinical trials for immunotherapies in the GBM field if the trial would be still ongoing?

why would Dr Bosch be at a conference if they are still in silent time?

why would Bosch want to be talking about Exploring immune therapy resistance in glioblastoma if the trial failed? TIf it failed then there is no response right?

and why would Dr Bosch still be employed if the trial has failed weeks before January 2022?

so the trial is a success and we will learn about it this year, Im pretty sure before Nov 1 given the financial situation they have put themselves in.